Global Cancer Diagnostics Market 2022 Growth, COVID Impact, Trends Analysis Report 2022-2031
Rising prevalence of cancer is likely to fuel the demand for
cancer diagnostics. A study by Future Market Insights (FMI) projects the cancer diagnostics market to surpass US$ 47.62 Bn in
2021. According to the World Health Organization (WHO), cancer is the second
-leading cause of death globally, accounting for over 9.9 million deaths in
2020. Rising cases of cancer have been fuelling the demand for advanced
diagnostics.
Technological advancements in various fields such as biopsy,
imaging, biomarkers and endoscopy, rising prevalence of cancer, increase in
government initiatives for creating awareness, rapidly increase in geriatric
population, and growing government funding are key factors driving the growth
of the cancer diagnostics market.
Get the Report Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1090
Timely detection of cancer requires suitable diagnostic
tests to screen the immunosuppressed population which is at moderate risk of
cancer, particularly for lung cancer, cervical cancer, breast cancer, prostate
cancer, colon cancer and melanoma. Growing awareness of early signs and
symptoms of cancer among physicians and other healthcare professionals as well
as among the general population supplements the growth of cancer diagnostics.
Inclusion of cancer screening tests in National Cancer Screening
Programs is another major factor expected to fuel the demand for cancer
diagnostics. Introduction of regular mammography into national cancer programs
by major developed countries where the incidence of breast cancer is high that
is leading towards increasing adoption of cancer diagnostics in developed
region.
For instance, the U.S. government has included the National
Mammography Program in its national cancer screening programs. The government
of Australia is taking initiative by conducting 3 cancer screening programs
such as the National Cervical Screening Program, BreastScreen Australia and the
National Bowel Cancer Screening Program. Similarly, most of the countries in
Europe are continuously adopting HPV DNA screening for cervical cancer as a part
of national cervical cancer programs.
Short-term Negative Impact Likely Due to COVID-19
The cancer diagnostics market is expected to experience
short-term negative growth owing to a reduction in the cancer diagnosis
procedures and adoption rate in developed and emerging countries. COVID-19 has
impacted the landscape of cancer diagnostics. This has affected demand in
various fronts, from prevention to screening and diagnosis, palliative care,
treatment, and patient follow-up, to logistics and supplies of cancer
diagnostic tests kits and other essential commodities.
Nonetheless after a period of muted growth, the market is
poised to recover as economies return to normalcy. As per FMI, the rising
incidence of lung cancer is attributable for over 19% of sales in the market.
Key Takeaways from Cancer Diagnostics Market Study
- The
rising incidence of cancer will fuel the demand for cancer diagnostics,
enabling the market register 8.5% CAGR between 2021 and 2022
- Increasing
cases of cancer in the U.S. accounts for 84% of demand in North America
- Increasing
healthcare spending will enable the U.K. market register over 5% y-o-y
growth in 2021
- Favorable
reimbursement policies will support growth in France and Germany
- Expansion
of the healthcare sector will support growth in Japan and South Korea
“Advancements in cancer diagnostics and rising
prevalence of cancer are expected to aid growth of cancer diagnostics. A
majority of leading players in cancer diagnostic market are adopting strategic
partnerships to sustain the increasing competitive pressure,” says the FMI
Analyst
Who is Winning?
Partnerships between cancer diagnostic assay kits
developers, instrument manufacturers and technology licensers are often
intended to increase the consumer base.
For instance, in March 2021, Illumina, Inc. signed a
partnership agreement with Geneseeq Technology Inc. to develop comprehensive
in-vitro diagnostic (IVD) NGS testing kits by using Illumina’s NextSeq 550Dx
sequencing platform for cancer.
In June 2020, Thermo Fisher Scientific signed an agreement
with Daiichi Sankyo to Co-launch a companion diagnostic for patients with
non-small cell lung cancer for identifying Her2 gene mutations using the
Oncomine Dx target test.
Want more insights?
Future Market Insights brings the comprehensive research
report on forecasted revenue growth at global, regional, and country levels and
provides an analysis of the latest industry trends in each of the sub-segments
from 2016 to 2031. The global cancer diagnostics market is segmented in detail
to cover every aspect of the market and present a complete market intelligence
approach to the reader. The study provides compelling insights on the cancer
diagnostics market on basis of the main test type in detail, cover every aspect
of the market such as Tumor Biomarkers Tests (PSA Tests, CTC Tests, AFP Tests,
CA Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests,
KRAS Mutation Tests, Others), Imaging (Ultrasound, Mammography, MRI Scan, PET
Scan, CT Scan, SPECT & Others), Biopsy (Needle Biopsy, Endoscopic Biopsy,
Bone Marrow Biopsy, Others), Liquid Biopsy, Immunohistochemistry and In Situ
Hybridization, indication (Breast Cancer, Lung Cancer, Colorectal Cancer,
Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver
Cancer and Others), and End-user (Hospital Associated Labs, Independent
Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes
and Others) across seven major regions.
About the Healthcare Division at Future Market Insights
Future Market Insights facilitates corporates, government,
investors, and associated audiences in the healthcare sector
to identify and accentuate vital aspects applicable to product strategy,
regulatory landscape, technology evolution, and other crucial issues to achieve
sustainable success. Our unique approach to gathering market intelligence
equips you in devising innovation-driven trajectories for your business. Know
more about our sector coverage here
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and
consulting services, serving clients in over 150 countries. FMI is
headquartered in Dubai, and has delivery centers in the UK, U.S. and India.
FMI’s latest market research reports and industry analysis help
businesses navigate challenges and make critical decisions with confidence and
clarity amidst breakneck competition. Our customized and syndicated market
research reports deliver actionable insights that drive sustainable
growth. A team of expert-led analysts at FMI continuously tracks emerging
trends and events in a broad range of industries to ensure that our clients
prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
Comments
Post a Comment